COMPARISON OF CLINICAL OUTCOMES OF SITAGLIPTIN ALONE AND COMBINATION OF METFORMIN+ GLIMEPRIDE IN THE MANAGEMENT OF UNCOMPLICATED TYPE 2 DIABETICS.

Dr. Jarinabanu Tahashildar, Dr. Ravi Shekhar singh, Dr. Jameela Tahasildar

Abstract


This study has evaluated two treatment antidiabetic regimens viz Sitagliptin alone and combination of Metformin+ Glimepride in type-2 diabetics.
The most common admitting outcomes assessed were glycemia control, and the incidence of complications. The results of this study reveal that the
combination regimen was more efficacious to achieve glycaemia control in comparison to monotherapy group.
Conclusion: The present study suggests that a significant difference may be existing in the clinical outcome interms of glycemia control and
complications between Sitagliptin alone and combination of Metformin+ Glimepride in type-2 diabetic patients.


Keywords


Type 2 DM Patients, Sitagliptin, Metformin+ Glimepride, Glycemia Control.

Full Text:

PDF

References


Kumar PJ, Clark M. Diabetes mellitus and other disorders of metabolism. Textbook of Clinical Medicine. Pub: Saunders (London) 2002;1099-1121.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.

Beverley B, Eschwège E. The diagnosis and classification of diabetes and impaired glucose tolerance. In: Textbook of Diabetes 1 Ed: John C Pickup and Gareth Williams Third edition; Chapter 2 2003;2.1-2.11.

Lindberg G, Lindblad U, Melander A. Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database Systemic Reviews 2004;(3).

Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications, estimates and projections to the year 2010. Diabetic Med 1997;14:1-85.

King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-1431.

Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted. J Med 2000;247:301-310.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.

UK prospective Diabetes study(UKPDS)Global prevalence of Diabetes: Estimate for the year 2000 and projections for 2030.Diabetes care 2004;27:1047-53.

Turner RC, Cull, Fright V, Holman RR. Glycemic control with diet, Sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).UK prospective Diabetes study (UKPDS) Group. JAMA 1999:281; 2005-12.

Choy M, Lam S. Sitagliptin: a nobel drug for the treatment of type 2 diabetes. Cardiol Rev 2007; 15:264-71.

InzucchiSE,Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and

troglitazone in type II diabtes mellitus. N Engl J Med 1998; 338: 867-872.

Product Information. JANUVIA (sitagliptin). White house Station: Merck & Co., Inc.

October 2006.

Davidson Ja, parent EB, Gross JL. Incretinmimetics and Dipeptidyl Peptidase- 4inhibitors;

Innovative treatment therapies for type 2 diabetes. Arq Bras EndocrinolMetab 2008;52/6:1039-49.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J,Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care2007;30:1979–87.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin, in patients with type 2 diabetes mellitus inadequatelycontrolled on glimepiride alone or on glimepiride and metformin.DiabetesObesMetab 2007;9:733–45.

Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673–80.

Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes ObesMetab 2002;4:368–75.

Duckworth W, Marcelli M, Padden M, Kellick K, Duhancik T, Wilhardt M, Colgan K, Romie A. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9:256–62.

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, KhatamiH. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM,Chatterjee R, et al. Comparative effectiveness and safetyof medications for type 2 diabetes: an update including newdrugs and 2-drug combinations. Ann Intern Med 2011;154:602–13.


Refbacks

  • There are currently no refbacks.